Echo IQ has developed an AI clinical decision-support tool that analyses echo measurement data to show risk indicators for structural heart disease.
EchoSolv™ AS has been clinically validated to identify up to 72% more high risk patients than found by cardiologists alone, including 100% identification of in-guideline severe Aortic Stenosis patients.
Dr. Playford, MBBS PhD FRACP (gen med) FRACP (cardiol) FCSANZ FACC FESC; Professor and Head of Cardiology, University of Notre Dame; consultant clinical and imaging cardiologist Advara HeartCare; Founder and Co-Chief Investigator National Echo Database Australia; Chief Medical Advisor Echo IQ.
Echo IQ Limited
EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full
phenotyping capabilities will be available pending FDA approval.